Gastrointestinal Cancer

Luis A. Diaz, MD, discusses the precision medicine approaches available and in development for the treatment of patients with GI malignancies.

The FDA has granted a priority review designation to a novel version of the radiopharmaceutical iobenguane I-131 for patients with malignant or recurrent pheochromocytoma or paraganglioma.

Daniel D. Von Hoff, MD, is focused on developing more targeted therapies for those with pancreatic and other advanced cancers.

Shirley Michelle Shiller, DO, discusses progress with precision medicine for patients with gastrointestinal cancers.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses frontline treatment options for patients with colorectal cancer (CRC).

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of radiation in the treatment of gastrointestinal malignancies.

Ghassan K. Abou-Alfa, MD, discusses what he sees coming down the pike in epatocellular carcinoma with regard to novel agents, including CAR T-cell therapy, and the burgeoning questions with optimal sequencing of these treatments.

Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.

William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.

The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.